Resistance and perspectives in soft tissue sarcomas by Komdeur, Rudy
  
 University of Groningen
Resistance and perspectives in soft tissue sarcomas
Komdeur, Rudy
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2003
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Komdeur, R. (2003). Resistance and perspectives in soft tissue sarcomas. s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the




Effects of TRAIL, doxorubicin and 4-hydroxy-ifosfamide in a 
panel of soft-tissue sarcoma cell lines with different sensitivity 
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Doxorubicin (DOX) and ifosfamide (IFO) are the most active single agents 
in soft tissue sarcomas (STS). Still, the response rate in metastatic disease 
is only 20-30%. Tumor necrosis factor-α (TNF-α) is used for STS only in 
the setting of isolated limb perfusions. Like TNF-α, TNF-related apoptosis-
inducing ligand (TRAIL) also induces apoptosis, and preliminary studies 
indicate that TRAIL lacks systemic side effects. Resistance to TRAIL has 
been demonstrated, but can be circumvented by combinations of TRAIL 
with conventional cytotoxic agents, in vitro. The effects of TRAIL alone 
and in combination with DOX or 4-hydroxy-IFO (i.e. the active metabolite 
of IFO, 4-OH-IFO) were evaluated in a panel of TNF-α sensitive and 
resistant human soft tissue sarcoma cells. 
The rhabdomyosarcoma cell line KYM-1, its five-fold TNF-α sensitive 
subline KD4 and its >150-fold TNF-α resistant subline 37B8R were used. 
Membrane expression of the TRAIL-receptors DR4, DR5 (pro-apoptotic) 
and DcR1, DcR2 (anti-apoptotic) was assessed by flow cytometry. Drug-
induced cytotoxicity was determined by a microculture tetrazolium assay. 
Apoptosis assays using acridine orange were conducted for the 
combination that was most potent of inducing cytotoxicity.  
DOX and 4-OH-IFO decreased survival in all cell lines; a two-fold 
resistance was observed for both drugs in 37B8R. All three cell lines 
expressed DR4 and DR5, but no or very low levels of DcR1 or DcR2. 
TRAIL single agent decreased survival in KYM-1 and was even more 
cytotoxic in KD4 and induced massive apoptosis, while 37B8R was >500-
fold resistant to TRAIL compared to KYM-1 and little apoptosis could be 
observed. The combination of TRAIL plus DOX showed synergistic 
cytotoxic effects in KYM-1 and 37B8R. The combination of TRAIL plus 
4-OH-IFO showed to be additive in all three cell lines. DOX plus TRAIL 
induced more cytotoxicity as well as apoptosis in all three cell lines 
compared to TRAIL alone. In 37B8R, DOX overcame resistance to 
TRAIL. 
In KYM-1 and its sublines KD4 and 37B8R, sensitivity and resistance 
to TNF-α and TRAIL parallels. TRAIL resistance was independent from 
expression of TRAIL receptors. DOX with TRAIL could overcome 
TRAIL-resistance in 37B8R cells, suggesting a therapeutic potential for 





Soft tissue sarcomas (STS) are the group of malignancies of mesenchymal 
origin. In case of metastatic disease, curation is difficult to reach with 
standard treatment, including doxorubicin (DOX) and ifosfamide (IFO). 
Therefore, finding alternative agents is critical. 
A potential innovative treatment implies the use of cytokines of the 
tumor necrosis factor (TNF) superfamily. Some members of this growing 
family have drawn attention as anticancer agents, including the prototype 
TNF-α that rapidly induces apoptosis in many cancer types. TNF-α in 
combination with melphalan is used in the setting of a hyperthermic 
isolated limb perfusion, resulting in a local response rate up to almost 90% 
in locally advanced STS.1 However, this regional treatment has no impact 
on the metastasis-free and overall survival of patients, while the systemic 
use of TNF-α is hampered by severe toxic side-effects.2,3 
TNF-related apoptosis-inducing ligand (TRAIL) is a more recently 
identified member of the TNF superfamily that selectively induces 
apoptosis in malignant cells.4,5 Native TRAIL is safe in non-human 
primates, while human tissues are spared at tumoricidal concentrations, 
suggesting that TRAIL is a candidate for systemic cancer treatment.6-8 
TRAIL is a type II transmembrane protein and so far, four membrane-
bound receptors for TRAIL have been described: DR4, DR5, DcR1 and 
DcR2. Apoptosis is mediated by the two death receptors DR4 and DR5, 
while the two decoy receptors DcR1 and DcR2 interrupt apoptosis.9 
The combination of TRAIL with cytotoxic agents offers several 
possibilities. First, TRAIL can increase sensitivity to cytotoxic agents, or 
even restore sensitivity in resistant cells. Second, cytotoxic agents can 
increase sensitivity to TRAIL-mediated apoptosis. Third, when 
combinations proof to be more effective than the single agents, lower 
amounts of the cytotoxic agents and TRAIL can be applied.  
The aim of the present study was to analyze the effect of cytotoxic 
agents (DOX and activated IFO) with the new apoptosis-inducing agent 
TRAIL in a panel of isogenic soft-tissue sarcoma cell lines. The panel 
consisted of the rhabdomyosarcoma cell line KYM-1, its TNF-α sensitive 
subline KD4 and its TNF-α resistant subline 37B8R. Cytotoxicity of the 
cytotoxic agents and TRAIL was tested alone and in combination. In 
addition, TRAIL receptor status of the cell lines was evaluated and 
apoptosis studies were performed under conditions of the most effective 
cytotoxic combinations. 
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Materials and Methods 
 
Chemicals. RPMI 1640 medium, L-glutamine and sodium pyruvate were 
obtained from Invitrogen (Merelbeke, Belgium), fetal calf serum (FCS) 
from Bodinco BV (Alkmaar, The Netherlands). TNF-α was kindly 
provided by Boehringer-Ingelheim (Ingelheim am Rhein, Germany). 
Recombinant human soluble TRAIL was made according Ashkenazi et al.6 
and was dissolved in medium with 10% FCS at a stock concentration of 
423 µg/ml. The active metabolite of IFO, 4-hydroxy-IFO (4-OH-IFO) was 
a gift from Asta Medica (Frankfurt, Germany). DOX (Adriablastina™) 
was obtained from Pharmacia & Upjohn (Woerden, The Netherlands). 
Sodium azide and acridine orange (AO) were purchased from Sigma (St 
Louis, MO, USA); AO was dissolved in demineralized water at a 1-mg/ml 
concentration. The ready-to-use tetrazolium dye solution Cell Proliferation 
Reagent WST-1 was purchased from Roche Diagnostics GmbH 
(Mannheim, Germany). Anti-DR4, -DR5, -DcR1, -DcR2 antibodies were a 
gift from Amgen (formerly Immunex; Thousand Oaks, CA, USA). FITC-
labelled rabbit-anti-mouse antibodies were bought from DAKO (Glostrup, 
Denmark). 
 
Cell lines and culturing. KYM-1, an embryonal rhabdomyosarcoma cell 
line 10 and the two sublines KD4 and 37B8R were kindly provided by A. 
Meager (National Institute for Biological Standards and Control, Potters 
Bar, UK). KYM-1 has been described as a TNF-α sensitive cell line.11-17 
KD4 was established after limited dilution cloning of KYM-1 cells and has 
increased sensitivity to TNF-α.11,18,19 37B8R cells are resistant to TNF-α, 
established after exposure to gradually increasing concentrations of TNF-
α.11 The cell lines were grown in RPMI 1640 medium supplemented with 
7% FCS, 1mM L-glutamine and 1mM sodium-pyruvate. Cells were 
incubated at 37°C with saturated humidity and 5% CO2. All three cell lines 
grow in suspension under increasing medium viscosity due to the 
production of hyaluronic acid.10 To avoid reproducibility problems due to 
handling cells under viscous conditions, cells were harvested for 
experiments at latest two days after addition of fresh medium.19 New 
passages of all three cell lines were started every three months. 
 
Cell viability assays. For cytotoxicity measurements, a modified 
microculture tetrazolium assay was used. This colorimetric assay is based 
on cleavage of the tetrazolium dye WST-1 (4-[3-(4-iodophenyl)-2-(4-
Chapter 8 
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nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) to water-soluble 
formazan by mitochondrial dehydrogenases in viable cells. The linear 
association between cell concentrations to the production of the formazan 
was confirmed and cell growth studies were performed to assure 
exponential cell growth at the time of measuring cell survival. For KYM-1 
and KD4, 1.2 × 104 cells per well and for 37B8R, 1.0 × 104 cells per well 
were incubated with single agent or combinations of DOX, 4-OH-IFO and 
TRAIL in a total volume of 200 µl, all in triplo. After 96 hours, 20 µl of the 
WST-1 solution was added and incubated for 3 hours at 37 °C. Formazan 
production was assessed by measuring the absorbance at a wavelength of 
450 nm on a scanning microplate spectrophotometer (Benchmark™ 
Microplate Reader, Bio-Rad Laboratories). 
Background absorbance was corrected by subtracting the absorbance 
measured for the culture medium in absence of cells. The percentage of 
cell survival was calculated as: 
 
% survival = (absorbance of experimental well / absorbance of untreated well) × 100 
 
Each experiment was performed in triplicate, with a minimum of three 
individual experiments per cell line per drug or combinations of drugs. 
 
Apoptosis assays. AO staining was used to distinguish apoptotic cells 
from vital cells.20 To analyze apoptosis induction, 6.0 × 104 cells per well 
were incubated in triplo with different concentrations of cytotoxic agent 
and/or TRAIL in a total volume of 200 µl into a 96-wells plate. Untreated 
cells were used as controls. After 24 hours of exposure, AO (final 
concentration: 5 ng/ml) was added and incubated at 37 °C for 10 minutes. 
Then cells were centrifuged at 900 rpm for 15 minutes. Three-quarter of 
the supernatant was removed and checked first for unintentional aspiration 
of cells before proceeding to counting cells under a fluorescent microscope 
(Olympus IM, Japan; wavelength 525 nm). The apoptotic index was 
calculated as: 
 
 % apoptosis = (number of apoptotic cells) / (total number of cells)  
 
A minimum of three independent experiments per single agent and 
combination per cell line was performed.  
 
Analysis of cell viability and apoptosis assays. To analyze the potential 
enhancing effects of the cytotoxic agents on TRAIL-mediated cytotoxicity 
TRAIL and cytotoxic agents in soft tissue sarcoma cells 
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and apoptosis, the enhancement ratio (ER) for each experiment was 
calculated. ER was calculated by dividing the effect of TRAIL alone by the 
effect of TRAIL combined with the cytotoxic agent, the latter corrected for 
the effect of cytotoxic agent alone.21 In concordance with previous studies, 
an ER-value between 0.8-1.2 was considered as indicative for additivity, 
ER lower than 0.8 as antagonistic and ER higher than 1.2 as synergistic. 
 
Expression of TRAIL receptors. Cells (1.0 × 105) were analyzed for 
DR4, DR5, DcR1 and DcR2 expression by flow cytometry, using receptor 
NH2-terminal-specific monoclonal antibodies. First, harvested cell were 
washed in phosphate buffered saline (PBS) with 2% FCS and 0.1% sodium 
azide. Cells were then incubated with the primary antibodies at 37 °C for 
30 minutes. After washing in PBS with 2% FCS and 0.1% sodium azide, 
cells were incubated with FITC-labelled rabbit-anti-mouse antibody for 30 
minutes while kept on ice. As control for auto-fluorescence, cells that were 
not incubated with the primary and secondary antibody were analyzed. As 
control for a-specific binding of the FITC-labelled secondary antibody, 
cells that were not incubated with the primary antibody were analyzed. 
Data from KD4 and 37B8R cells were compared with those of the parental 





Effect of DOX, 4-OH-IFO and TRAIL on cell survival. The sensitivity 
profiles of the three cell lines to TNF-α as previously described 11 were 
confirmed by a pilot study (data not shown). 
Table 1 shows the sensitivity of the three cell lines to the tested drugs: 
DOX, 4-OH-IFO and TRAIL. The IC50 (concentration inhibiting cell 
survival by 50%) level for KYM-1 and KD4 was reached at similar 
concentrations of both DOX and 4-OH-IFO, while 37B8R was a factor 2 
resistant compared to KYM-1 for both drugs. 
TRAIL by itself had a strong cytotoxic effect on both KYM-1 and KD4. 
At the highest concentrations tested (5µg/ml), the cytotoxic effect of 
TRAIL on KYM-1 was 60%, while for KD4 over 90% cytotoxicity was 
reached. On the contrary, TRAIL alone had limited effect on 37B8R, never 
capable of inducing more than 25% cytotoxicity. The drug concentrations 
used in the combination experiments were titrated on a range of 25 to 75% 
cytotoxicity (when feasible). 
Chapter 8 
Table 1. IC50 values for single-agents DOX, 4-OH-IFO and TRAIL in KYM-1, KD4 and 
37B8R cell lines 
 
 KYM-1 KD4 37B8R 
 mean SD mean SD mean SD 
DOX [nM] 3.10 ± 0.63 3.84 ± 0.45 6.1 ± 2.20 
4-OH-IFO [nM] 254 ± 126 172 ± 150 538 ± 261 
TRAIL [µg/ml] 0.0065 ± 0.0018 0.0047 ± 0.0037 >5  
 
Abbreviations: IC50, concentration inhibiting cell survival by 50%; DOX, doxorubicin; 
4-OH-IFO, 4-hydroxy-ifosfamide; TRAIL, tumor necrosis related apoptosis-inducing 
ligand; SD, standard deviation 
 
Figure 1 shows the effects of combining DOX with TRAIL in the KYM-1 
cell line. Both DOX and TRAIL individually decreased cell survival. At all 
tested concentrations, DOX and TRAIL were able to induce extra cell 
death. The enhanced cytotoxic effect became also evident in TRAIL-
resistant 37B8R cells (Figure 2). For the tested combinations of DOX, 
37B8R cells were sensitized to TRAIL-mediated cytotoxicity. When 
comparing absolute cell survival at isomolar concentrations, KYM-1 was 
found to be more sensitive to this combination than 37B8R at DOX [3nM] 
and TRAIL [0.001 µg/ml], but these cell lines were equally sensitive at 



































Figure 1. Sensitivity of KYM-1 to DOX, TRAIL and combinations of these two drugs 
(96-hours continuous incubation) as measured in a modified microculture tetrazolium 
assay 
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Figure 2. Sensitivity of 37B8R to DOX, TRAIL and combinations of these two drugs (96-




Table 2 summarizes the enhancement ratio (ER) found for the combination 
of DOX and TRAIL in the three cell lines. Combining TRAIL with DOX 
shows synergy (ER > 1.20) in especially KYM-1 and 37B8R, with the 
effect being most stable in the 37B8R cell line.  
The combined effects of 4-OH-IFO and TRAIL have been depicted in 
Table 3, showing the calculated ER’s. For all combinations and all cell 
lines, additivity was observed. 
 
Table 2. DOX and TRAIL 
 
 Table 3. 4-OH-IFO and TRAIL 
 








































































(Table 2. continued) 
 
 (Table 3. continued) 




















































         


















































Enhancement ratio’s of modified microculture tetrazolium assays for KYM-1, KD4 and 
37B8R cell lines at indicated concentrations of DOX and TRAIL (Table 2) 
and 4-OH-IFO and TRAIL (Table3). 
(standard deviation indicated between brackets; synergistic interactions highlighted in 
bold) 
 
Induction of apoptosis. The combination DOX plus TRAIL was further 
investigated in apoptosis assays, as this combination gave rise to the most 
pronounced effects in the cytotoxicity assays. AO staining was used to 
distinguish apoptotic cells from viable cells.20 After incubation with AO, 
apoptotic cells were recognized as cells with condensed chromatin, 
whether intact or already fragmented, intensely staining with AO. 
Membrane blebbing with shedding of apoptotic bodies was considered as 
an alternative hallmark of apoptosis. Viable cells had loosely packed 
(“extended”) chromatin with an intact cellular membrane. Because of the 
shorter incubation period for apoptosis assays, higher concentrations of 
TRAIL and DOX were used compared to the modified microculture 
tetrazolium assays. 























Figure 3. Induction of apoptosis by DOX, TRAIL and combinations of these two 







































Figures 3a, 3b and 3c show the results of apoptosis assays in KYM-1, KD4 
and 37B8R, respectively. While single-agent induced apoptosis in KYM-1 
and KD4 cells, the combination of the two agents increased the percentage 
of apoptotic cells. KYM-1 and KD4 revealed similar pattern in sensitivity 
to TRAIL and DOX; still, apoptosis was more pronounced in KD4. After 
24 hours of exposure, more KD4 cells than KYM-1 cells were in an 
advanced stage of apoptosis, with fragmented chromatin and membrane 
blebbing. Contrary, a relatively small percentage of 37B8R cells revealed 
features of apoptosis after exposure to DOX and higher doses of TRAIL 
(Figure 3c). Still, the combination of TRAIL with DOX resulted in a 
marked increase of apoptosis (Figure 3c). A dramatic increase of apoptosis 
in 37B8R was observed when DOX [375 nM] was combined with TRAIL, 
either [0.05µg/ml] or [0.25µg/ml].  
Similar to the analysis of modified microculture tetrazolium assays, 
ER’s were calculated for the induction of apoptosis by the combination of 
DOX and TRAIL and are show in Table 4. Synergistic apoptosis induction 
by DOX plus TRAIL was observed for all three cell lines at most 
concentrations tested. In KYM-1, synergistic ER-values were observed 
especially at the higher DOX concentrations. Noticeable, the apoptosis 
induction was quite variable at the highest concentrations. This variability 
was even higher in KD4 cells, with extremely high ER’s as a result of 
maximal apoptosis induction. Still, at the lower concentrations of DOX 
[75nM], the effect remains synergistic even though to a lesser degree, yet 
more stable as indicated by the narrower standard deviation. The 
synergistic effect of DOX and TRAIL on apoptosis induction was present 
as well in 37B8R, although less pronounced than in the other two cell 
lines. However, while TRAIL and DOX alone did scarcely induce 
apoptosis, their combination showed apoptosis induction comparable to the 
KYM-1 cell line. Moreover, the synergistic effect in 37B8R at the higher 
concentrations of DOX [375 nM] was found to be the most stable of all 
three cell lines. Higher concentrations of TRAIL were required for 37B8R 
to obtain similar levels of apoptosis compared to KYM-1, illustrative of a 
more resistant phenotype. 
TRAIL and cytotoxic agents in soft tissue sarcoma cells 
Table 4. Enhancement ratio’s of apoptosis induction in KYM-1, KD4 and 37B8R cell 
lines at indicated concentrations of DOX and TRAIL. 
(standard deviation indicated between brackets; synergistic interactions highlighted in 
bold; n.t. = not tested) 
 
 DOX [nM] KYM-1 
 15 75 375 
 0.002 n.t. 1.18 (0.07) 2.60 (0.40) 
TRAIL [µg/ml] 0.01 1.22 (0.14) 1.42 (0.26) 7.14 (4.15) 
 0.05 1.69 (0.71) 2.85 (0.90) n.t. 
     
 DOX [nM] KD4 
 15 75 375 
 0.002 n.t. 1.54 (0.21) 18.4 (18.7) 
TRAIL [µg/ml] 0.01 1.05 (0.32) 3.16 (0.88) 28.8 (11.8) 
 0.05 0.81 (0.38) 2.59 (2.86) n.t. 
     
 DOX [nM] 37B8R 
 15 75 375 
 0.01 1.01 (0.05) 1.06 (0.06) n.t. 
TRAIL [µg/ml] 0.05 1.08 (0.07) 1.06 (0.03) 2.55 (0.46) 




TRAIL receptor membrane expression. KYM-1, KD4 and 37B8R 
expressed DR4 and DR5, while no or very low levels of DcR1 or DcR2 
could be detected. Compared to KYM-1, KD4 expressed factor 1.5 to 2 
less DR4, and comparable levels of DR5. Compared to KYM-1, 37B8R 





STS comprise a heterogeneous group of malignancies, sharing their origin 
from primitive mesenchymal cells. As a whole, STS are notorious for early 
hematogenous spread. The presence of (micro-) metastases limits the 
curative use of local treatments (surgery and radiotherapy), rendering 
chemotherapy as the only tumor-directed therapy. 
Anticancer drugs exert their cytotoxic effect through the induction of 
apoptosis in tumor cells. Blockades in the complex routes leading to 
apoptosis may consequently convey resistance to anticancer drugs. One 




with alternative apoptosis inducing agents. TRAIL is a newly described 
apoptosis-inducing member of the TNF superfamily of cytokines, which 
might be of value for these purposes.22 
The aim of the present study was to analyze the combined effect of the 
two most active cytotoxic agents in STS, i.e. DOX and activated IFO, with 
the new apoptosis-inducing agent TRAIL in a panel of rhabdomyosarcoma 
cell lines. 
The cell lines selected for the current study were initially reported for 
their sensitivity to TNF-α, the prototype of the TNF superfamily. In later 
studies, additional data became available for the sensitivity profile to other 
TNF family cytokines: TRAIL, Fas Ligand, TWEAK.23,24 This panel 
represents a unique model of related soft tissue sarcoma cell lines with 
different sensitivity to the TNF family of cytokines, including TRAIL. 
These characteristics allow exploring the effects of combining cytotoxic 
agents with TRAIL on TRAIL-sensitive, but even more importantly, 
TRAIL-resistant STS cells. 
DOX and 4-OH-IFO were both capable of inducing cytotoxicity in all 
three cell lines. As the cell lines have been established in the absence of 
cytotoxic anticancer agents, no mechanisms of drug resistance driven by 
the exposure to such drugs could have been evolved. Still, the IC50 to 
DOX and 4-OH-IFO for the TNF-α/TRAIL resistant cell line 37B8R was 
higher than for the TNF-α/TRAIL sensitive cell lines KYM-1 and KD4. 
KYM-1 and KD4 were both sensitive to TRAIL-mediated cytotoxicity. 
However, while for KD4 nearly complete cell kill could be achieved, a 
survival of approximately 40% of KYM-1 cells was still observed at the 
highest tested concentration of TRAIL (5 µg/ml). Caron et al. reported that 
KD4 cells were resistant to TRAIL at concentrations up to 0.2 µg/ml.19 
This difference with the current study might be attributed to molecular 
differences in TRAIL used (we used native TRAIL versus His-tag TRAIL 
in the study of Caron) and the method to detect apoptosis (morphological 
versus flow cytometric analysis of annexin V flip-flop to the external 
membrane leaflet). The concentrations of TRAIL applied in the present 
study are corresponding to those of former in vitro and in vivo studies, at 
which levels clearly identifiable anticancer results were achieved.6,22 We 
observed that KD4 was the most sensitive cell line to TRAIL: after 24 hr 
exposure to TRAIL, KD4 cells were already in an advanced stage of 
apoptosis. Contrary, TRAIL was able to induce 20% cytotoxicity 
maximum in 37B8R at the tested range of concentrations. Concerning this 
TRAIL resistance of 37B8R cells, the current study comes to similar 
TRAIL and cytotoxic agents in soft tissue sarcoma cells 
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findings to that of the study by Caron et al. In an earlier study on single-
agent TRAIL, Petak et al. reported that four out of a panel of seven 
rhabdomyosarcoma (not KYM-1) cell lines were sensitive to TRAIL.25 
However, in the three TRAIL-resistant cell lines, an additional factor 
would have been required to achieve significant anticancer effects. 
Therefore, in the current study we tested TRAIL single agent, but we also 
tested the interaction of TRAIL with cytotoxic agents. 
Combining DOX with TRAIL resulted in an increased effect on cell kill 
in all three rhabdomyosarcoma cell lines tested. In KYM-1 and KD4, in 
which substantial cell kill could be achieved with TRAIL single agent, 
DOX could still contribute to the cytotoxicity. Interesting, in 37B8R, 
TRAIL alone lacked a significant cytotoxic effect, whereas combination 
with DOX was able to overcome TRAIL-resistance. In 37B8R, the 
synergistic effect as determined by ER was the most stable in repeated 
experiments. 
In the laboratory setting, the combination of DOX with TRAIL has 
proven to be effective in killing epithelial cancer cell lines: prostate 26-28, 
breast 29-31, liver 32, lung 30,33, ovarian 30,34, colon 30,35, squamous cell 30, 
melanoma 30; hematological cancer cell lines 36-38, and mesenchymal 
cancer cell lines.39,40 Clayer et al. described the effects of TRAIL and DOX 
in primary cultures obtained from three STS of different histological type 
(rhabdomyosarcoma, fibrosarcoma and malignant fibrous histiocytoma).41 
In their study, TRAIL alone had no cytotoxic effect. The combination of 
TRAIL, however, led to overtly more cytotoxicity in the respective cell 
lines than DOX alone. The combined effect of TRAIL and DOX was more 
pronounced compared to the combinations of TRAIL with cisplatin, 
etoposide, methotrexate or cyclophosphamide. 
To our knowledge, this is the first report on the effect of activated IFO 
and TRAIL. Overall, combinations showed an additive cytotoxic effect on 
the three tested cell lines. Evdokiou reported on TRAIL with 
cyclophosphamide, a drug that is structurally related to IFO, on osteogenic 
sarcoma cells.40 In these cells, cyclophosphamide alone did not induce 
cytotoxicity within the tested range of concentrations, nor did it enhance 
TRAIL-mediated cytotoxicity. However, it remains uncertain whether the 
investigators had used cyclophosphamide as a pro-drug or in its activated 
form. Of interest, drug resistant tumor cells can develop cross-resistance to 
pro-apoptotic cytokines.42 As mentioned, combining these cytokines with 
cytotoxic agents might still overcome this resistance. In the current model 
the combination of DOX and TRAIL prevailed over that of 4-OH-IFO and 
Chapter 8 
 129 
TRAIL. The molecular mechanisms by which DOX and TRAIL aid each 
other in killing cancer cells remain to be investigated. 
The underlying mechanism of sensitivity to TRAIL in tumor cells is 
poorly understood. Apoptosis is mediated by the two death receptors DR4 
and DR5, while the two decoy receptors DcR1 and DcR2 interrupt 
apoptosis. The cell lines presented here expressed similar levels of DR4 
and DR5, while DcR1 and DcR2 were absent or nearly detectable. While 
expression of the death receptors DR4 and DR5 is essential for TRAIL-
induced apoptosis, the presented results suggest that their level of 
expression is not determinative for the sensitivity to TRAIL. Several 
factors are uncovered that can influence this machinery to reach this final 
goal. Amongst these are the pro-apoptotic factors caspases 8 and 10 9, and 
Bax 43, and the anti-apoptotic factor FLIP 44, the family of inhibitors of 
apoptosis proteins (IAP’s) 45 and the Bcl-2 family.46 Much is yet unclear 
about the contribution of these individual factors and it appears 
conceivable that differences exist on their role between tumors. Laboratory 
studies continue to uncover the very multifactorial nature of resistance to 
TRAIL. In this context it is difficult to define a clinically applicable target 
to circumvent TRAIL-resistance. Meanwhile, as suggested by the current 
study and others, conventional cytotoxic agents appear a realistic approach 
to this purpose. Still, it remains a challenge to search for non-toxic agents 
with these properties.  
In the rhabdomyosarcoma cell line KYM-1 and its sublines KD4 and 
37B8R, sensitivity to TNF-α and TRAIL paralleled. TRAIL-sensitivity and 
-resistance was independent from TRAIL receptor expression, suggesting 
that one or more downstream apoptotic blocks exist in TRAIL resistant 
37B8R cells. The data presented here show that in the TRAIL sensitive 
lines KYM-1 and KD4, enhanced cytotoxicity could be achieved when 
combining TRAIL with DOX or 4-OH-IFO. Importantly, in the TRAIL 
resistant cell line 37B8R, DOX with TRAIL could overcome TRAIL-
resistance, suggesting a therapeutic potential for this combination for TNF-
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